Logo image of RARE

ULTRAGENYX PHARMACEUTICAL IN (RARE) Stock Fundamental Analysis

USA - NASDAQ:RARE - US90400D1081 - Common Stock

33.92 USD
-0.48 (-1.4%)
Last: 10/21/2025, 10:30:00 AM
Fundamental Rating

3

RARE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. Both the profitability and financial health of RARE have multiple concerns. RARE is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RARE has reported negative net income.
In the past year RARE has reported a negative cash flow from operations.
RARE had negative earnings in each of the past 5 years.
In the past 5 years RARE always reported negative operating cash flow.
RARE Yearly Net Income VS EBIT VS OCF VS FCFRARE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

RARE has a Return On Assets of -40.80%. This is comparable to the rest of the industry: RARE outperforms 58.99% of its industry peers.
The Return On Equity of RARE (-352.27%) is worse than 73.22% of its industry peers.
Industry RankSector Rank
ROA -40.8%
ROE -352.27%
ROIC N/A
ROA(3y)-41.44%
ROA(5y)-32.95%
ROE(3y)-214.63%
ROE(5y)-141.85%
ROIC(3y)N/A
ROIC(5y)N/A
RARE Yearly ROA, ROE, ROICRARE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

RARE's Gross Margin of 85.32% is amongst the best of the industry. RARE outperforms 88.02% of its industry peers.
In the last couple of years the Gross Margin of RARE has remained more or less at the same level.
RARE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.3%
GM growth 5Y-1.12%
RARE Yearly Profit, Operating, Gross MarginsRARE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K -200K

More info and screens

3

2. Health

2.1 Basic Checks

RARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RARE has more shares outstanding
The number of shares outstanding for RARE has been increased compared to 5 years ago.
RARE has a better debt/assets ratio than last year.
RARE Yearly Shares OutstandingRARE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
RARE Yearly Total Debt VS Total AssetsRARE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of -3.22, we must say that RARE is in the distress zone and has some risk of bankruptcy.
RARE has a Altman-Z score (-3.22) which is comparable to the rest of the industry.
A Debt/Equity ratio of 5.17 is on the high side and indicates that RARE has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 5.17, RARE is doing worse than 82.21% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 5.17
Debt/FCF N/A
Altman-Z -3.22
ROIC/WACCN/A
WACC9.12%
RARE Yearly LT Debt VS Equity VS FCFRARE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

A Current Ratio of 2.45 indicates that RARE has no problem at all paying its short term obligations.
RARE has a Current ratio of 2.45. This is in the lower half of the industry: RARE underperforms 69.29% of its industry peers.
RARE has a Quick Ratio of 2.30. This indicates that RARE is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.30, RARE is not doing good in the industry: 68.73% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.45
Quick Ratio 2.3
RARE Yearly Current Assets VS Current LiabilitesRARE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

7

3. Growth

3.1 Past

RARE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.25%, which is quite impressive.
RARE shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.76%.
RARE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 40.13% yearly.
EPS 1Y (TTM)24.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.03%
Revenue 1Y (TTM)26.76%
Revenue growth 3Y16.82%
Revenue growth 5Y40.13%
Sales Q2Q%13.24%

3.2 Future

Based on estimates for the next years, RARE will show a very strong growth in Earnings Per Share. The EPS will grow by 25.18% on average per year.
The Revenue is expected to grow by 32.57% on average over the next years. This is a very strong growth
EPS Next Y18.92%
EPS Next 2Y16.21%
EPS Next 3Y22.55%
EPS Next 5Y25.18%
Revenue Next Year20.11%
Revenue Next 2Y21.69%
Revenue Next 3Y29.87%
Revenue Next 5Y32.57%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
RARE Yearly Revenue VS EstimatesRARE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
RARE Yearly EPS VS EstimatesRARE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10 -10 15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RARE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RARE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RARE Price Earnings VS Forward Price EarningsRARE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RARE Per share dataRARE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

RARE's earnings are expected to grow with 22.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.21%
EPS Next 3Y22.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RARE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ULTRAGENYX PHARMACEUTICAL IN

NASDAQ:RARE (10/21/2025, 10:30:00 AM)

33.92

-0.48 (-1.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners100.2%
Inst Owner Change-0.98%
Ins Owners3.49%
Ins Owner Change1.3%
Market Cap3.27B
Analysts85.19
Price Target85.68 (152.59%)
Short Float %8.66%
Short Ratio4.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.14%
Min EPS beat(2)4.6%
Max EPS beat(2)11.68%
EPS beat(4)3
Avg EPS beat(4)4%
Min EPS beat(4)-5.63%
Max EPS beat(4)11.68%
EPS beat(8)5
Avg EPS beat(8)1.98%
EPS beat(12)6
Avg EPS beat(12)-7.84%
EPS beat(16)7
Avg EPS beat(16)-9.28%
Revenue beat(2)1
Avg Revenue beat(2)-2.02%
Min Revenue beat(2)-5.05%
Max Revenue beat(2)1.02%
Revenue beat(4)3
Avg Revenue beat(4)0.18%
Min Revenue beat(4)-5.05%
Max Revenue beat(4)4.02%
Revenue beat(8)5
Avg Revenue beat(8)0.25%
Revenue beat(12)6
Avg Revenue beat(12)-1.15%
Revenue beat(16)7
Avg Revenue beat(16)-1.53%
PT rev (1m)0%
PT rev (3m)-2.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.03%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.85%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.36
P/FCF N/A
P/OCF N/A
P/B 21.61
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.53
EYN/A
EPS(NY)-4.12
Fwd EYN/A
FCF(TTM)-4.59
FCFYN/A
OCF(TTM)-4.37
OCFYN/A
SpS6.33
BVpS1.57
TBVpS-0.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.8%
ROE -352.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.32%
FCFM N/A
ROA(3y)-41.44%
ROA(5y)-32.95%
ROE(3y)-214.63%
ROE(5y)-141.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.3%
GM growth 5Y-1.12%
F-Score2
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 5.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.4%
Cap/Sales 3.45%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.45
Quick Ratio 2.3
Altman-Z -3.22
F-Score2
WACC9.12%
ROIC/WACCN/A
Cap/Depr(3y)346.02%
Cap/Depr(5y)389.65%
Cap/Sales(3y)18.19%
Cap/Sales(5y)18.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.03%
EPS Next Y18.92%
EPS Next 2Y16.21%
EPS Next 3Y22.55%
EPS Next 5Y25.18%
Revenue 1Y (TTM)26.76%
Revenue growth 3Y16.82%
Revenue growth 5Y40.13%
Sales Q2Q%13.24%
Revenue Next Year20.11%
Revenue Next 2Y21.69%
Revenue Next 3Y29.87%
Revenue Next 5Y32.57%
EBIT growth 1Y7.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.09%
EBIT Next 3Y27.06%
EBIT Next 5YN/A
FCF growth 1Y20.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.17%
OCF growth 3YN/A
OCF growth 5YN/A